Osprey Medical (ASX:OSP) - President & CEO, Mike McCormick
President & CEO, Mike McCormick
Source: Finance News Network
Market Herald logo


Be the first with the news that moves the market
  • Medical imaging specialist Osprey Medical (OSP) landed a four-year distribution deal with global medical giant GE Healthcare today
  • Under the deal, GE Healthcare will distribute Osprey’s products to some key global markets over the next four years
  • With GE Healthcare bringing in around $16.7 billion in annual revenue, this is the biggest deal signed by Osprey in company history
  • Osprey’s FDA-approved DyeVert technology is designed to reduce the amount of medical dye used in heart imaging procedures
  • This in turn dramatically reduces the risk of a patient developing acute kidney injury (AKI)
  • GE Healthcare is one of the biggest producers of medical dye for imaging in the world
  • Shares in Osprey are trading over four per cent higher today, currently worth 4.7 cents each

Medical imaging specialist Osprey Medical (OSP) landed a four-year distribution deal with global medical giant GE Healthcare today.

Under the deal, GE will exclusively distribute Osprey’s products in Europe, Russia, the Middle East, Central Asia, and Turkey.

Osprey said with GE Healthcare’s $16.7 billion in annual revenue, today’s contract is the single biggest agreement ever signed by the company.

Kidney protection

At the forefront of the distribution deal is Osprey’s DyeVert product, which is designed to reduce the risk of kidney damage for people undergoing heart imaging procedures.

The medical dye used in these procedures, which is referred to as “contrast”, can cause a condition known as acute kidney injury (AKI) when used to x-ray the hearts of people with chronic kidney disease.

The damage to the kidneys can range from loss of kidney function to complete kidney failure, and as such the risk of AKI is a major concern for hospitals. According to Osprey, roughly one in every four patients undergoing heart imaging procedures are at risk of developing AKI.

The company’s DyeVert device reduces the amount of contract required in these imaging procedures by around 40 per cent — without affecting the quality of the image for the physician.

With less dye used, the risk of AKI is dramatically lowered. Osprey’s tech is the only U.S. Food and Drug Administration (FDA)-approved device of its kind.

Why GE Healthcare?

As part of its product offering, GE Healthcare manufactures contrast dye for heart imaging procedures. This means today’s deal with Osprey is a strong vote of confidence for the ASX-listed company’s tech.

According to Osprey, someone is imaged using a GE Healthcare product once every three seconds around the world. GE Healthcare will now be commercializing Osprey’s dye-reducing tech across some key markets.

Thus, while today’s deal may not come with any direct revenue figures, Osprey said it expects the contract to add “materially” to company revenue and drive double-digit growth in the next year alone.

Kevin O’Neill, the President and CEO of GE Healthcare’s Pharmaceutical Diagnostics business, spoke highly of the Osprey tech.

“GE Healthcare and Osprey share a similar goal rooted in improving patient outcomes,” Kevin said.

“Both our product portfolios and educational efforts, which are aligned with cardiology guidelines for KAI minimization, offer interventional cardiologists the opportunity to safely image patients by reducing the risk of AKI,” he said.

Today, Osprey shares are trading 4.44 per cent higher and worth 4.7 cents each. The company has a $70.44 million market cap.

OSP by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.